Silymarin for COVID-19: real-time analysis of 2 studies

Download Image

Post

c19early.org

Silymarin for COVID-19

1 study with 50 patients

Serious outcome risk

Silymarin

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Silymarin studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−20%

Hospitalization (1)8%

RCTs (1)−20%

Late (1)−20%

00.511.5+

← Silymarin
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Sep 16 2024	Emam et al., AMB Express, doi:10.1186/s13568-024-01739-8	Establishment of in-house assay for screening of anti-SARS-CoV-2 protein inhibitors
	In vitro study showing that curcumin, quercetin, gallic acid, and silymarin inhibit SARS-CoV-2 spike protein binding to the ACE2 receptor. Authors developed a novel immunofluorescent assay to screen potential inhibitors of the spike-ACE2 ..
Jul 20 2022	Aryan et al., Phytotherapy Research, doi:10.1002/ptr.7537	Evaluation of the efficacy of oral nano‐silymarin formulation in hospitalized patients with COVID‐19: A double‐blind placebo‐controlled clinical trial
	20% higher need for oxygen therapy (p=0.78) and 8% shorter hospitalization (p=0.5). RCT 50 hospitalized COVID-19 patients showing no significant difference in symptom resolution time or hospitalization duration with nano-silymarin treatment.